SELL ALERT: Agios Pharmaceuticals

9th October 2018 | Eoin Treacy

I have been monitoring Agios Pharmaceuticals closely and following the action we saw on Friday I believe the position should now be sold.

Agios has been drifting lower since testing the psychological $100 level in July and I have been willing to give it the benefit of the doubt as it reverted to the mean. It needed to push back above the trend mean last week, to demonstrate a return to demand dominance, but instead dropped to a new low.

This occurred against a background where there has been a dearth of new news from the company and the CEO is exercising options to buy more stock. However, the pullback in Sangamo Therapeutics is weighing on some of the immuno-oncology shares and I believe that this is one of the primary reasons for the recent weakness. It does not make sense to argue with the message being sent by the market and therefore Agios is now a sell.

The longer-term potential for immuno-oncology remains undiminished and I anticipate that the sector will return to performance over the coming months. When I see evidence of that happening I will make a fresh recommendation to buy into the sector. 

Action to take: Sell Agios Pharmaceuticals
Ticker: AGIO
Price recommended at: $83.05
Last close (as at 08/10/2018): $69.01

All the best,

Eoin Treacy
Investment Director, Frontier Tech Investor

Subscribe Now
Show Sitemap
PUBLICATIONS
USEFUL LINKS
SOUTHBANK INVESTMENT RESEARCH

You don’t need more information to be a better, more profitable investor. You need better research. Here you’ll find investment ideas and strategies from some of Britain’s most experienced investors produced specifically for investors like you. Learn more about independent stock market research and advice from one of the UK’s oldest financial publishers.

  • Save
  • Print

Important Risk Warning

Advice in Altucher’s Investment Network Pro UK does not constitute a personal recommendation.

Any advice should be considered in relation to your own circumstances, risk tolerance and investment objectives. Before investing you should carefully consider the risks involved, including those described below. If you have any doubt as to suitability or taxation implications, seek independent financial advice.

General – Your capital is at risk when you invest, never risk more than you can afford to lose. Past performance and forecasts are not reliable indicators of future results. Bid/offer spreads, commissions, fees and other charges can reduce returns from investments. There is no guarantee dividends will be paid.

Small cap shares - Shares recommended may be small company shares. These can be illiquid meaning they are hard to trade and can have a large bid/offer spread. If you need to sell soon after you bought, you might get back less that you paid. This makes them riskier than other investments in larger share companies.

Overseas investments - Shares may be denominated in a currency other than sterling. The return from these may increase or decrease as a result of currency fluctuations. Any dividends will be taxed at source in the country of issue.

Unregulated investments - The Financial Conduct Authority does not regulate certain activities, including the buying and selling of commodities. This means that you will not have the protection of the Financial Ombudsman Service or the Financial Services Compensation Scheme.

Taxation – Profits from share dealing are a form of income and subject to taxation. Tax treatment depends on individual circumstances and may be subject to change.

Managing Editor: Sam Volkering. Editors or contributors may have an interest in shares recommended. Information and opinions expressed do not necessarily reflect the views of other editors/contributors of Southbank Investment Research Limited.

Full details of our complaints procedure, privacy policy and terms and conditions can be found at, www.southbankresearch.com.

Altucher’s Investing Network PRO UK is published in the UK with licenced content from Paradigm Press LLC. It contains regulated content and is issued by Southbank Investment Research Limited. Registered in England and Wales No 9539630. VAT No GB629 7287 94. Registered Office: Basement, 95 Southwark Street, London, SE1 0HX.

Contact Us: To contact customer services, please call us on 0203 966 4580, Monday to Friday, 10.00am – 5.00pm.

Southbank Investment Research Limited is authorised and regulated by the Financial Conduct Authority. FCA No 706697. https://register.fca.org.uk/.

© 2025 Southbank Investment Research Limited.

Registered in England Company No 9539630. VAT No GB629 7287 94. Registered Office: Basement, 95 Southwark Street, London SE1 0HX.

Southbank Investment Research Limited is authorised and regulated by the Financial Conduct Authority. FCA No 706697 https://register.fca.org.uk/

© 2026 Southbank Investment Research Ltd.